賽諾菲-安萬特 SNY 深 滬
等待開盤 03-26 09:30:00 美东时间
46.03
+0.890
+1.97%
華盛通- 最 高46.40
- 今 開45.92
- 成交量 185.59万股
- 最 低 45.75
- 昨 收 45.14
- 總市值 1111.66亿
- 52周最高 54.1314
- 市盈率 靜 19.21
- 換手率 0.08%
- 52周最低 43.32
- 委 比 74.20%
- 總股本 24.15亿
- 歷史最高 58.5164
- 量 比 0.43
- 振 幅 1.44%
- 歷史最低 15.4368
- 每 手 1
- 風險率 2.15%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多上海市静安区发布外资转型“静八条”
（来源：经济日报） 转自：经济日报 记者日前从上海市静安区召开的2026年外资外贸转型升级推进大会获悉，静安区支持外资（总部）企业转型发展能级提升八条举措（以下...
03-25 14:55
专利悬崖压顶！跨国药企集体瘦身，赛诺菲减员超 8000 人
（来源：抗体圈） 行业格局逆转：从普遍扩张到集体收缩 对比近年数据，制药行业用人策略出现根本性反转。2022 年，17 家大型药企中仅 3 家启动裁员；到...
03-24 15:34
赛诺菲中国研发中心全面战略升级
来源：美通社 上海 2026年3月23日 /美通社/ -- 今日，赛诺菲在上海市静安区召开的2026年外资外贸转型升级推进大会上宣布，对现有中国研发中心进行全...
03-24 14:22
Regeneron And Sanofi's Dupixent Approved In Japan As First Targeted Medicine For Adults With Moderate-To-Severe Bullous Pemphigoid
Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placeboBP is a chronic,
03-24 14:16
Japan MHLW approves Dupixent for moderate-to-severe bullous pemphigoid adults
Japan MHLW approves Dupixent for moderate-to-severe bullous pemphigoid adults Japan’s health ministry approved Dupixent (dupilumab) to treat adults with moderate-to-severe bullous pemphigoid, according to Regeneron and Sanofi. In the LIBERTY-BP-ADEPT Phase 2/3 trial, sustained disease remission at W
03-24 14:01
新浪财经ESG：赛诺菲安万特 MSCI（明晟）ESG评级调升至AA
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点击查看【 ESG评级中...
03-24 10:29
聚焦四大核心方向 打破重销售轻研发布局 激活外资创新内生动力 静安加码外资研发创新扶持
来源：解放日报 记者 唐烨 昨天，在静安区召开的外资外贸转型升级推进大会上，静安发布了支持外资（总部）企业转型发展能级提升八条举措（以下简称“静八条”...
03-24 09:03
Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)
The Japanese Ministry of Health has approved Dupixent (dupilumab) for treating adults with moderate-to-severe bullous pemphigoid (BP), a rare, chronic skin disease characterized by type 2 inflammation. Approval is based on pivotal trial results showing Dupixent achieved sustained disease remission in over four times as many patients as placebo by Week 36. BP, primarily affecting the elderly, causes severe itching, painful blisters, and lesions. T...
03-24 06:00
Eupraxia Pharmaceuticals Boasts $900 Million Peak Sales Potential: Analyst
William Blair starts Eupraxia at Outperform as the analyst flags unmet need and sizable market potential.
03-24 01:59
